Conduct↦Monitoring↦Routine Monitoring Visit↦Follow-Up
What is it? Why is it important?
After a Routine-Monitoring-Visit (RMV), the monitor follows-up on site progress in order to ensure outstanding RMV findings are properly addressed. The aim is to ensure the ongoing right and safety (i.e. study risk-benefit) of study participant, including and the confidentiality and quality of study data.
During RMV follow-up, the site is expected to resolve outstanding issues within a given timeline. This is especially the case regarding serious findings (e.g. safety and quality concerns).
In the event a RMV finding cannot be resolved during follow-up, the SP-INV performs a risk-assessment in order to decide whether the study must:
- Be put on hold until an acceptable resolution of the finding is found
- Be adapted in order control for the finding. An adaptation in study conduct will require a protocol amendment with subsequent approval by Ethics Committee (EC) and if applicable RA (e.g. Swissmedic). In the event participants become affected, they may also have to reconsent
What do I need to do?
As a study monitor responsible for site follow-up:
- Write a short follow-up letter or e-mail to the Site-INV and:
- Transmit the follow-up letter/e-mail within 10 to 20 business days, or as soon as possible in the event of serious findings
- Remotely check and answer ingoing queries regarding outstanding issues
- Inform the study SP-INV of findings that remain unresolved, or in the event of site non-compliance
Follow-up activities may address the:
- Disposal or accountability of the investigational therapeutic product (e.g. IMP / IMD) or material (e.g. vaccination vials, unused /returned tablets, dysfunctional medical device)
- Ordering of investigational product or other study material including delivery at study site
- The forwarding of essential documents needed for ISF filing
- Update the study TMF (e.g. monitoring report, new staff qualification and training)
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- Glossary: definition monitoring
- Glossary: definition monitoring report
- 3.10.1.3 Risk control
- 3.11.4 Monitoring
- 3.11.4.5 Monitoring activities
- 3.11.4.5.1 Communication with parties conducting the trial
ICH E8 – see in particular guideline
- 6.3 Study reporting
- 6.2.1 Safety monitoring
ISO 14155 Medical Device – see in particular section (access liable to costs)
- 9.2.4 Monitoring